Abstract | BACKGROUND: METHODS AND RESULTS:
Bucindolol is a nonselective beta-blocking agent with mild vasodilatory properties. One hundred forty-one subjects with class II or III heart failure, left ventricular ejection fraction (LVEF) < or = 0.40, and background therapy of angiotensin-converting enzyme inhibitors, digoxin, and diuretics were given an initial challenge dose of bucindolol 12.5 mg. One hundred thirty-nine subjects (99 with IDC, 40 with ISCDC) tolerated challenge and were randomized to treatment with placebo or bucindolol 12.5 mg/d (low dose), 50 mg/d (medium dose), or 200 mg/d (high dose). At the end of 12 weeks, left ventricular function and other parameters were measured and compared with baseline values. There was a dose-related improvement in left ventricular function in bucindolol-treated subjects. In the high-dose bucindolol group, radionuclide-measured LVEF improved by 7.8 EF units (%) compared with 1.8 units in the placebo group (P < .05), and compared with the placebo group, a greater percentage of subjects had an increase in LVEF by > or = 5 units. In contrast, all three bucindolol doses prevented deterioration of myocardial function as defined by an LVEF decline of > or = 5 units. CONCLUSIONS: In heart failure from systolic dysfunction, beta-blockade with bucindolol produces a dose-related improvement in and prevents deterioration of left ventricular function.
|
Authors | M R Bristow, J B O'Connell, E M Gilbert, W J French, G Leatherman, N E Kantrowitz, J Orie, M L Smucker, G Marshall, P Kelly |
Journal | Circulation
(Circulation)
Vol. 89
Issue 4
Pg. 1632-42
(Apr 1994)
ISSN: 0009-7322 [Print] United States |
PMID | 7908610
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic beta-Antagonists
- Propanolamines
- bucindolol
|
Topics |
- Adrenergic beta-Antagonists
(administration & dosage, therapeutic use)
- Cardiomyopathy, Dilated
(complications)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Heart Failure
(drug therapy, epidemiology, etiology)
- Humans
- Male
- Middle Aged
- Propanolamines
(administration & dosage, therapeutic use)
- Prospective Studies
- Ventricular Function, Left
(drug effects)
|